H.C. Wainwright Downgrades Galectin Therapeutics (GALT) to Neutral Dec 27, 2024 12:32PM
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2023 and Provides Business Update May 15, 2023 08:00AM
Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Investment Conference May 2, 2023 Apr 27, 2023 08:00AM
UPDATE: Galectin Therapeutics to Participate in the H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021 Oct 5, 2021 03:39PM
Galectin Therapeutics (GALT) PT Raised to $12 at H.C. Wainwright May 15, 2018 07:13AM


Dec 7, 2017 07:18AM Galectin Therapeutics (GALT) PT Raised to $10 at H.C. Wainwright; Market Got it Wrong
Nov 28, 2017 07:23AM Galectin Therapeutics (GALT): Low Data Hurdle In Early Dec, PT To $6 - HC Wainwright
Mar 30, 2017 07:06AM H.C. Wainwright Upgrades Galectin Therapeutics (GALT) to Buy, Major Catalyst in Dec.
Sep 29, 2016 07:06AM H.C. Wainwright Downgrades Galectin Therapeutics (GALT) to Neutral
Sep 21, 2016 10:53AM Galectin Therapeutics (GALT) Gains Again on Takeover, NASH Trial Speculation
Sep 20, 2016 01:09PM Galectin Therapeutics (GALT) May Have Best Read-Through From Allergan's Tobira (TBRA) Deal - H.C. Wainwright's Arce